Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation.

Simple item page
dc.contributor.authorUdomsakdi-Auewarakul, Chirayuen_US
dc.contributor.authorVisuthisakchai, Sananen_US
dc.contributor.authorSangruchi, Tumtipen_US
dc.contributor.authorIssaragrisil, Surapolen_US
dc.date.accessioned2009-05-27T17:21:27Z
dc.date.available2009-05-27T17:21:27Z
dc.date.issued2003-06-25en_US
dc.descriptionPublished by the Allergy and Immunology Society of Thailand.en_US
dc.description.abstractAgnogenic myeloid metaplasia (AMM) is a clonal hematopoietic stem cell disorder characterized by bone marrow fibrosis, extramedullary hemopoiesis, splenomegaly and a leukoerythroblastic blood picture. Current standard therapies using hydroxyurea, interferon, androgens or corticosteroids have not shown to prolong survival of patients with AMM. In this study, we performed a curative approach using an HLA-matched sibling as a donor for allogeneic peripheral blood stem cell transplantation (PBSCT) for a 45-year-old woman with AMM. Busulfan and cyclophosphamide were given as a conditioning regimen from day -7 to day -2 with cyclosporinA and methotrexate as post-transplant immunosuppressive therapy. Donor PBSCs were mobilized by G-CSF at 16 microg/kg/day for five days and transplantation was performed on March 2-3, 2000. The patient rapidly engrafted within 2 weeks after PBSC infusion without evidence of graft versus host disease. Her blood counts and bone marrow 2 years after transplantation were normal with full donor pattern by molecular analysis. In conclusion, marrow fibrosis can be reverted to normal by allogeneic PBSCT. Allogeneic PBSCT should thus be offered to AMM patients if an HLA-matched sibling is available. This report represents the first SCT for AMM in Thailand.en_US
dc.description.affiliationChulabhorn Bone Marrow Transplantation Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.en_US
dc.identifier.citationUdomsakdi-Auewarakul C, Visuthisakchai S, Sangruchi T, Issaragrisil S. Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation. Asian Pacific Journal of Allergy and Immunology. 2003 Jun; 21(2): 121-6en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/37015
dc.language.isoengen_US
dc.subject.meshBusulfan --therapeutic useen_US
dc.subject.meshCyclophosphamide --therapeutic useen_US
dc.subject.meshCyclosporine --therapeutic useen_US
dc.subject.meshFemaleen_US
dc.subject.meshGranulocyte Colony-Stimulating Factor --therapeutic useen_US
dc.subject.meshHLA Antigens --immunologyen_US
dc.subject.meshHistocompatibility --immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunosuppressive Agents --therapeutic useen_US
dc.subject.meshMethotrexate --therapeutic useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPeripheral Blood Stem Cell Transplantationen_US
dc.subject.meshPrimary Myelofibrosis --immunologyen_US
dc.subject.meshTransplantation, Homologousen_US
dc.titleReversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation.en_US
dc.typeCase Reportsen_US
dc.typeJournal Articleen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Asian Pacific Journal of Allergy and Immunology